blacklist of drugs most dangerous in 2023
Here is the blacklist of drugs considered the most dangerous in 2023
If medicines are our daily ally, some of them are dangerous to health. Like every year, the medical journal Prescrire puts out a blacklist of drugstore references to avoid. This assessment aims to help patients "choose good care" and limit harm to their health.
In 2023, no fewer than 107 medicines will be included in this list, of
which 88 are marketed in France. According to Prescrire, each of them has an "unfavorable balance of risks and benefits." We take stock of the major changes between the 2022 report and this year's report.
Prescrire's blacklist: 3 new drugs to avoid
In the medical journal's camera lens, there are 3 new drugs in 2023:
Peanut Seed Powder Containing Peanut Protein (Palforzia°):
“Approved for desensitization in cases of peanut allergy,” and this product is said to tend to “increase the frequency of allergic reactions in daily life,” according to the description.
Roxadustat (Evrenzo°):
“Indicated in the treatment of anemia associated with renal failure
chronic," this drug "appears to increase mortality in some patients."
Opium tincture (Dropizal°):
“allowed in cases of severe diarrhoea”, this “soup” of various poppy components “provides no clinical advantage compared to loperamide” (an opioid marketed alone in this case).
Reference returned to the list
From year to year, Prescrire's list of dangerous drugs is evolving. It happens that some references disappear before the big return. Such is the case of nintedanib, "a tyrosine kinase inhibitor with antiangiogenic effect, which is permitted in some non-small cell lung cancers (under the name Vargatef°) and in some chronic lung conditions (under the name Ofev°)".
While being removed from the roster in 2021, Prescrire made the decision to reinstate him. To explain this choice, the medical journal states: “Analysis of clinical evaluation data showed that the benefit-risk balance for nintedanib is unfavorable. It is therefore again among the drugs to be excluded.”
Also to read
Medications removed from the list set by Prescrire
The other novelty is that two properties have been removed from the balance sheet for 2023. These two properties will not be listed until they are revalued. These are idebenone (Raxone°) and teriflunomide (Aubagio°). Prescrire's 2024 report may tell us more about the fate of these drugs.
Ghano Dzpro
Ghano Dzpro is the founder of this Blog. It's the creative mind behind KLWP themes and KWGT widgets and Pinterest content, as well as the editor. Ghano Dzpro mostly covers mobile and app content, as he has experience in these topics.
